Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4997-5001

  Cao, Deliang ^a   Nimmakayalu, Manjunath A ^a   Wang, Feiya ^a   Zhang, Dekai ^a   Handschumacher, Robert E ^a   Bray Ward, Patricia ^a   Pizzorno, Giuseppe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; URIDINE PHOSPHORYLASE;

ARTICLE; CHROMOSOME MAP; DNA FLANKING REGION; EXON; GENE SEQUENCE; GENE STRUCTURE; INTRON; MOLECULAR CLONING; MOUSE; NONHUMAN; ONCOGENE C H RAS; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0033215234     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Liu, M-P., Cao, D-L., Russell, R. L., Handschumacher, R. E., and Pizzorno, G. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res., 58: 5418-5424, 1998.
2. Chu, S. Y., Weng, Z. Y., Chen, Z. H., Rowe, E. C., Chu, E., Naguib, F. N. M., el Kouni, M. H., Cha, S., and Chu, M. Y. Synthesis of 5-benzyl and 5-benzyloxybenzyl 2,2′-anhydrouridines and related nucleoside analogs as inhibitors of uridine phosphorylase. Nucleosides Nucleotides, 7: 91-102, 1988.
3. Darnowski, J. W., and Handschumacher, R. E. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res., 45: 5364-5368, 1985.
4. Martin, D. S., Stolfi, R. L., and Sawyer, R. C. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother. Pharmacol., 24: 9-14, 1989.
5. Monks, A., Ayers, O., and Cysyk, R. L. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem. Pharmacol., 32: 2003-2009, 1983.
6. Birnie, G. D., Kroeger, H., and Heidelberger, C. Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase. Biochemistry, 2: 566-572, 1963.
7. Chu, M. Y. B., Naguib, F. N. M., Itzsch, M. H., el Kouni, M. H., Chu, S. H., Cha, S., and Calabresi, P. Potentiation of 5-fluoro-2′-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine. Cancer Res., 44: 1852-1856, 1984.
8. Ishitsuka, H., Miwa, M., Takemoto, K., Fukuoka, K., Itoga, A., and Maruyama, H. B. Role of uridine phosphorylase for antitumor activity in 5′-deoxy-5-fluorouridine. Gann, 71: 112-123, 1980.
9. Woodman, P. W., Sarrif, A. M., and Heidelberger, C. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′-deoxyuridine. Cancer Res., 40: 507-511, 1980.
10. Pizzorno, G., Yee, L., Burtness, B. A., Marsh, J. C., Darnowski, J. W., Chu, M. Y., Chu, S. H., Leffert, J. J., Handschumacher, R. E., and Calabresi, P. Clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor, Clin. Cancer Res., 4: 1165-1175, 1998.
11. Liu, M-P., Beigelman, L., Levy, E., Handschumacher, R. E., and Pizzorno, G. The discrete roles of hepatocytes and nonparenchymal cells in uridine catabolism as a component of its homeostasis. Am. J. Physiol., 274: G1018-G1023, 1998.
12. Seiter, K., Kemeny, N., Martin, D., Schneider, A., Williams, L., Colofiore, J., and Sawyer, R. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-1-aspartate, methotrexate, and leucovorin. Cancer (Phila.), 71: 1875-1881, 1993.
13. Van Groeningen, C. J., Leyva, A., Kraal, I., Peters, G. J., and Pinedo, H. M. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat. Rep., 70: 745-750, 1986.
14. Niedzwicki, J. G., el Kouni, M. H., Chu, S. H., and Cha, S. Pyrimidine acyclonucleosides, inhibitors of uridine phosphorylase. Biochem. Pharmacol., 30: 2097-2101, 1981.
15. Geng, Y., Gheuens, E., and De Bruijn, E. A. Activation and cytotoxicity of 5′-deoxy-5-fluorouridine in c-h-ras transformed NIH 3T3 cells. Biochem. Pharmacol., 41: 301-303, 1991.
16. Eda, H., Fujimoto, K., Watanabe, S., Ishikawa, T., Ohiwa, T., Tatsuno, K., Tanaka, Y., and Ishitsuka, H. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5-deoxy-5-fluoruridine. Jpn. J. Cancer Res., 84: 341-347, 1993.
17. Watanabe, S., Hino, A., Wada, K., Eliason, J. F., and Uchida, T. Purification, cloning, and expression of murine uridine phosphorylase. J. Biol. Chem., 270: 12191-12196, 1995.
18. Watanabe, S., and Uchida, T. Cloning and expression of human uridine phosphorylase. Biochem. Biophys. Res. Commun., 216: 265-272, 1995.
19. Wadler, S., Schwartz, E. L., Goldman, M., Lyver, A., Rader, M., Zimmerman, M., Itri, L., Weinberg, V., and Wiernik, P. H. Fluorouracil and recombinant α-2a-interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol., 7: 1769-1775, 1989.
20. Houghton, J. A., Morton, C. L., Adkins, D. A., and Rahman, A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-α2a in colon carcinoma cells. Cancer Res., 52: 4243-4250, 1993.
21. Sawyer, J. R., Moore, M. M., and Hozier, J. C. High resolution G-banded chromosomes of the mouse. Chromosoma (Berl.), 95: 350-358, 1987.
22. Ried, T., Baldini, A., Rand, T. C., and Ward, D. C. Simultaneous visualization of the seven different DNA probes by in situ hybridization using combinatorial fluorescence and digital imaging microscopy. Proc. Natl. Acad. Sci. USA, 89: 1388-1392, 1992.
23. Boyle A. L., Feltquite, D. M., Dracopoli, N. C, Housman, D. E., and Ward, D. C. Rapid mapping of cloned DNA on banded mouse chromosomes by fluorescence in situ hybridization. Genomics, 12: 106-115, 1992.
24. Proudfoot, N. J. How RNA polymerase II terminates transcription in higher eukaryotes. Trends Biochem. Sci., 14: 105-110, 1989.
25. Hahnen, E., Schonling, J., Rudnik-Schoneborn, S., Zerres, K., and Wirth, B. Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease. Am. J. Hum. Genet., 59: 1057-1065, 1996.
26. Pizzorno, G., Cheng, Y. C., and Handschumacher, R. E. Pyrimidine, and purine antimetabolites. In: Cancer Medicine, 4th ed., pp. 923-948. Baltimore, MD: Williams & Wilkins, 1996.
27. Jonsson, J. J., Williams, S. R., and McIvor, R. S. Sequence and functional characterization of the human purine nucleoside phosphorylase promoter. Nucleic Acids Res., 19: 5015-5020, 1991.
28. Hagiwara, K., Stenman, G., Honda, H., Sahlin, P., Andersson, A., Miyazono, K., Heldin, C. H., Ishikawa, F., and Takaku, F. Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene. Mol. Cell. Biol., 11: 2125-2132, 1991.
29. Orkin, S. H. GATA-binding transcription factors in hematopoietic cells. Blood, 80: 575-581, 1992.
30. Maeda, M., Kubo, K., Nishi, T., and Futai, M. Roles of gastric GATA DNA-binding proteins. J. Exp. Biol., 199: 513-520, 1996.
31. Escalante, C. R., Yie. J., Thanos, D., and Aggarwal, A. K. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature (Lond.), 391: 103-106, 1998.
32. Henderson, Y. C., Chou, M., and Deisseroth, A. B. Interferon regulatory factor-1 induces the expression of the interferon-stimulated genes. Br. J. Haematol., 96: 566-575, 1997.
33. Grandori, C., and Eisenman, R. N. Myc target genes. Trends Biochem. Sci., 22: 177-181, 1997.
34. Ishida, S., Takada. S., and Koike, K. Isolation and analysis of cellular DNA fragments directly binding to c-Myc protein. Leukemia (Baltimore), 3: 399-401, 1997.
35. Rudolph, C., Halle, J. P., and Adam, G. Accelerated proliferative senescence of rat embryo fibroblasts after stable transfection of multiple copies of the c-Myc DNA-binding sequence. Exp. Cell. Res., 239: 361-369, 1998.
36. Anderson, M. E., Woelker, B., Reed. M., Wang, P., and Tegtmeyer, P. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. Mol. Cell. Biol., 17: 6255-6264, 1997.
37. Muller-Tiemann, B. F., Halazonetis, T. D., and Elting, J. J. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci. USA, 95: 6079-6084, 1998.
38. Verhaegh, G. W., Parat, M. O., Richard, M. J., and Hainaut, P. Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. Mol. Carcinog., 21: 205-214, 1998.
39. Gritzmacher, C. A. Molecular aspects of heavy-chain class switching. Crit. Rev. Immunol., 9: 173-200, 1989.
40. Nicholls, R. D., Fischel-Ghodsian, N., and Higgs, D. R. Recombination at the human α-globulin gene cluster: sequence features and topological constraints. Cell, 49: 369-378, 1987.
41. Furukawa, T., Yoshimura, A., Sumizawa, T., Haraguchi, M., Akiyama, S., Fukui, K., Ishizawa, M., and Yamada, Y. Angiogenic factor. Nature (Lond.), 356: 668, 1992.